GenMont Biotech Incorporation (3164.TW)
TWD 19.95
(-1.24%)
TWD 19.95
(-1.24%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 2.71 Million TWD | 102.74% |
| 2022 | -99.14 Million TWD | 27.75% |
| 2021 | -137.22 Million TWD | 42.95% |
| 2020 | -240.51 Million TWD | -51.25% |
| 2019 | -159.01 Million TWD | 29.36% |
| 2018 | -225.1 Million TWD | -33.35% |
| 2017 | -168.81 Million TWD | 3.62% |
| 2016 | -175.15 Million TWD | -90.13% |
| 2015 | -92.12 Million TWD | 69.23% |
| 2014 | -299.42 Million TWD | -172.27% |
| 2013 | -109.97 Million TWD | 78.38% |
| 2012 | -508.58 Million TWD | 5.3% |
| 2011 | -537.04 Million TWD | 31.87% |
| 2010 | -788.22 Million TWD | -140.04% |
| 2009 | -328.37 Million TWD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 7.43 Million TWD | 174.04% |
| 2024 Q2 | -82.08 Million TWD | -1204.45% |
| 2023 Q4 | 2.71 Million TWD | 127.2% |
| 2023 FY | 2.71 Million TWD | 102.74% |
| 2023 Q2 | -107.52 Million TWD | -164.01% |
| 2023 Q3 | -9.97 Million TWD | 90.73% |
| 2023 Q1 | -40.72 Million TWD | 58.92% |
| 2022 Q1 | -56.45 Million TWD | 58.86% |
| 2022 Q2 | -245.74 Million TWD | -335.29% |
| 2022 FY | -99.14 Million TWD | 27.75% |
| 2022 Q4 | -99.14 Million TWD | 18.89% |
| 2022 Q3 | -122.23 Million TWD | 50.26% |
| 2021 FY | -137.22 Million TWD | 42.95% |
| 2021 Q1 | -207.09 Million TWD | 13.89% |
| 2021 Q2 | -127.15 Million TWD | 38.6% |
| 2021 Q3 | -111.19 Million TWD | 12.55% |
| 2021 Q4 | -137.22 Million TWD | -23.41% |
| 2020 Q2 | -163.99 Million TWD | -19.24% |
| 2020 Q3 | -285.89 Million TWD | -74.34% |
| 2020 Q4 | -240.51 Million TWD | 15.87% |
| 2020 Q1 | -137.52 Million TWD | 13.52% |
| 2020 FY | -240.51 Million TWD | -51.25% |
| 2019 Q1 | -246.86 Million TWD | -9.67% |
| 2019 Q3 | -251.52 Million TWD | 16.53% |
| 2019 Q4 | -159.01 Million TWD | 36.78% |
| 2019 FY | -159.01 Million TWD | 29.36% |
| 2019 Q2 | -301.32 Million TWD | -22.06% |
| 2018 Q2 | -1.02 Billion TWD | -659.31% |
| 2018 Q4 | -225.1 Million TWD | 28.95% |
| 2018 FY | -225.1 Million TWD | -33.35% |
| 2018 Q1 | -135.41 Million TWD | 19.78% |
| 2018 Q3 | -316.84 Million TWD | 69.19% |
| 2017 Q2 | -194.33 Million TWD | 3.49% |
| 2017 FY | -168.81 Million TWD | 3.62% |
| 2017 Q4 | -168.81 Million TWD | -1.65% |
| 2017 Q3 | -166.07 Million TWD | 14.54% |
| 2017 Q1 | -201.37 Million TWD | -14.97% |
| 2016 Q1 | -79.12 Million TWD | 14.11% |
| 2016 Q2 | -102.15 Million TWD | -29.11% |
| 2016 Q3 | -96.41 Million TWD | 5.62% |
| 2016 Q4 | -175.15 Million TWD | -81.67% |
| 2016 FY | -175.15 Million TWD | -90.13% |
| 2015 Q1 | -185 Million TWD | 38.21% |
| 2015 Q3 | -146.84 Million TWD | -18.4% |
| 2015 Q2 | -124.02 Million TWD | 32.96% |
| 2015 FY | -92.12 Million TWD | 69.23% |
| 2015 Q4 | -92.12 Million TWD | 37.26% |
| 2014 Q4 | -299.42 Million TWD | -337.27% |
| 2014 FY | -299.42 Million TWD | -172.27% |
| 2014 Q2 | 189.17 Million TWD | 2.97% |
| 2014 Q3 | 126.19 Million TWD | -33.29% |
| 2014 Q1 | 183.71 Million TWD | 267.05% |
| 2013 Q2 | -86.46 Million TWD | 87.99% |
| 2013 Q3 | 321.43 Million TWD | 471.77% |
| 2013 Q4 | -109.97 Million TWD | -134.21% |
| 2013 FY | -109.97 Million TWD | 78.38% |
| 2013 Q1 | -720.01 Million TWD | -41.57% |
| 2012 Q4 | -508.58 Million TWD | 8.34% |
| 2012 Q3 | -554.87 Million TWD | -6.64% |
| 2012 Q2 | -520.33 Million TWD | 49.14% |
| 2012 Q1 | -1.02 Billion TWD | -90.48% |
| 2012 FY | -508.58 Million TWD | 5.3% |
| 2011 Q1 | -554.6 Million TWD | 29.64% |
| 2011 Q2 | -330.03 Million TWD | 40.49% |
| 2011 Q3 | -541.16 Million TWD | -63.97% |
| 2011 Q4 | -537.04 Million TWD | 0.76% |
| 2011 FY | -537.04 Million TWD | 31.87% |
| 2010 FY | -788.22 Million TWD | -140.04% |
| 2010 Q4 | -788.22 Million TWD | 0.0% |
| 2009 FY | -328.37 Million TWD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Apex Biotechnology Corp. | -201.21 Million TWD | 101.348% |
| Sinphar Pharmaceutical Co.,Ltd. | 870.53 Million TWD | 99.688% |
| Panion & Bf Biotech Inc. | 193.2 Million TWD | 98.596% |
| Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 939.54 Million TWD | 99.711% |
| Abnova (Taiwan) Corporation | -415.8 Million TWD | 100.652% |
| Adimmune Corporation | 685.12 Million TWD | 99.604% |
| Tanvex BioPharma, Inc. | 1.35 Billion TWD | 99.799% |
| Polaris Group | -2.41 Billion TWD | 100.112% |
| Energenesis Biomedical CO.,LTD. | -246.6 Million TWD | 101.1% |
| UnicoCell Biomed Co., Ltd. | 54.43 Million TWD | 95.017% |
| PELL Bio-Med Technology Co. Ltd. | 4.88 Million TWD | 44.438% |